AGP Executive Report
Last update: 8 hours agoHIV Prevention Update: A study at AIDS 2026 found lenacapavir for PrEP made up only about 1% of U.S. PrEP use in the first half of 2025, with uptake mirroring existing disparities by race, ethnicity, and age. Medicaid Enforcement: CMS’s Medicaid Fraud War Room says it stopped more than $203 million in improper payments in under 90 days by targeting high-risk providers. Non-Opioid Pain Breakthrough: Latigo Biotherapeutics’ investigational non-opioid LTG-001 (a Nav1.8 inhibitor) reduced moderate-to-severe pain after abdominoplasty in a phase 2b trial. Cancer Care Expansion: The FDA approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) plus androgen receptor pathway inhibitor therapy for PSMA-positive metastatic prostate cancer earlier in the disease course. Regulatory Watch: An FDA advisory committee voted against recommending deramiocel approval for Duchenne muscular dystrophy cardiomyopathy, signaling a tough path ahead. Healthcare Policy: AHA urged CMS to reconsider parts of the Medicaid community engagement rule, while CMS issued multiple FY 2027 payment and rule updates affecting hospitals and long-term care. Industry & Workforce: Pharmacists in Nigeria called for a National Postgraduate College of Pharmacy to address specialist workforce shortages. Global Health Diplomacy: A U.S. envoy said there’s “incredible potential” to deepen investment and economic ties with Bangladesh, including a planned visit by U.S. companies.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Arpit Patel. Pharm.D., MedImpact]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/24374845-877653404-logo-100x22.png){kind=logo}
